Focusing on the advancements in nuclear medicine, this issue of PET Clinics delves into the diagnosis and treatment of neuroendocrine neoplasms, emphasizing theranostics. It explores various imaging techniques, including SPECT and PET tracers like F-DOPA and Ga-DOTA-peptides, along with Yttrium- and Lutetium-based therapies. Additionally, the role of FDG PET in managing these tumors is highlighted, providing essential insights into current practices and innovations in the field.
Furthermore, in general only a low-dose CT scan is produced as part of the combined PET/CT study, and the resulting CT images may prove suboptimal for image interpretation. This atlas is designed to enable nuclear medicine practitioners who routinely read PET/CT scans to recognize the most common CT abnormalities.
PET-CT is increasingly being employed in the diagnosis of both oncological and non-oncological patients, yet nuclear medicine physicians may have only limited practical experience of rare diseases and may experience difficulty in recognizing and interpreting rare findings. This unique atlas documents a large number of clinical cases that will help practitioners to identify findings and diseases that, though rare, are sufficiently frequent to be encountered in routine practice. Two types of cases are presented: patients evaluated for rare diseases and patients evaluated for standard diseases in whom atypical PET findings were detected. Each reported case includes a brief description of the clinical history, representative color PET-CT images obtained using FDG or other tracers, and a short explanation of the disease and findings. This atlas will enable practitioners to make conclusive reports of PET-CT scans that would otherwise have been inconclusive.